|
|
|
|
Managing Directors |
Jeff Himawan, Ph.D., has over 20 years of experience as a scientist, entrepreneur and venture capitalist. He began his industrial career in 1987 as a bench scientist at Genzyme Corporation. In 1996, Dr. Himawan co-founded Seed-One Ventures, a venture capital firm that specializes in the initial formation, financing, and early operational development of technology-based companies. As a Managing Director at Seed-One Ventures, he led the formation and management of
Elusys Therapeutics, Inc., a Fund IV
company. He has written several patents in the fields of biotechnology and protein chemistry.
Dr. Himawan first joined Essex Woodlands in 1999 as an Adjunct Partner;
he became a Partner in 2001. He serves on the Board of
Directors of Catalyst Biosciences, Inc ,
MediciNova, Inc. (NYSE: MNOV),
Light Sciences
Oncology, Inc.,
Ception Therapeutics, Inc.,
Horizon
Therapeutics, Inc. and Symphogen A/S.
Dr. Himawan holds a B.S. degree from the Massachusetts
Institute of Technology and a PhD degree in
Biological Chemistry and Molecular Pharmacology from Harvard University. |
|
|
 |
|
|
|
